Notch signalling pathway as an oncogenic factor involved in cancer development

Marlena Brzozowa-Zasada; Adam Piecuch; Anna Dittfeld; Łukasz Mielańczyk; Marek Michalski; Grzegorz Wyrobiec; Marzena Harabin-Słowińska; Józef Kurek; Romuald Wojnicz

doi:10.5114/wo.2016.61845

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2016
vol. 20

Send email

Copy url:

abstract:

Review paper

Notch signalling pathway as an oncogenic factor involved in cancer development

Marlena Brzozowa-Zasada

,

Adam Piecuch

,

Anna Dittfeld

,

Łukasz Mielańczyk

,

Marek Michalski

,

Grzegorz Wyrobiec

,

Marzena Harabin-Słowińska

,

Józef Kurek

,

Romuald Wojnicz

Contemp Oncol (Pozn) 2016; 20 (4):267-272

DOI: https://doi.org/10.5114/wo.2016.61845

Online publish date: 2016/09/05

View full text Get citation

PlumX metrics:

Notch signalling is an evolutionarily conserved signalling pathway, which plays a significant role in a wide array of cellular processes including proliferation, differentiation, and apoptosis. Nevertheless, it must be noted that Notch is a binary cell fate determinant, and its overexpression has been described as oncogenic in a broad range of human malignancies. This finding led to interest in therapeutically targeting this pathway especially by the use of GSIs, which block the cleavage of Notch at the cell membrane and inhibit release of the transcriptionally active NotchIC subunit. Preclinical cancer models have clearly demonstrated that GSIs suppress the growth of such malignancies as pancreatic, breast, and lung cancer; however, GSI treatment in vivo is associated with side effects, especially those within the gastrointestinal tract. Although intensive studies are associated with the role of -secretase in pathological states, it should be pointed out that this complex impacts on proteolytic cleavages of around 55 membrane proteins. Therefore, it is clear that GSIs are highly non-specific and additional drugs must be designed, which will more specifically target components of the Notch signalling.

keywords:

Notch signalling pathway as an oncogenic factor involved in cancer development

Marlena Brzozowa-Zasada , Adam Piecuch , Anna Dittfeld , Łukasz Mielańczyk , Marek Michalski , Grzegorz Wyrobiec , Marzena Harabin-Słowińska , Józef Kurek , Romuald Wojnicz

Notch signalling, cancer, GSIs

Marlena Brzozowa-Zasada

,

Adam Piecuch

,

Anna Dittfeld

,

Łukasz Mielańczyk

,

Marek Michalski

,

Grzegorz Wyrobiec

,

Marzena Harabin-Słowińska

,

Józef Kurek

,

Romuald Wojnicz